Phase 1 Study of Reboxetine Adjuvant Therapy and Cognitive and Behavioral Measures

NCT00409201 Phase 1 UNKNOWN

30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study period.

Details

Lead sponsor	Abarbanel Mental Health Center
Phase	Phase 1
Status	UNKNOWN
Enrolment	30
Start date	2006-03
Completion	2006-11

Conditions

• Schizophrenia

Interventions

• reboxetine adjuvant therapy

Primary outcomes

• sans, panss, hamilton, ham-a, calgary, physical examination, cogscan test

Countries

Israel